New drug may tame rare vasculitis and cut steroid dependence

This study tests whether a drug called mepolizumab can help people with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA) reach remission better than standard treatments. About 100 adults with active EGPA will receive either mepolizumab or usual care, and doctors will track how much steroid medication they need. The goal is to see if mepolizumab allows patients to use lower steroid doses without their disease flaring up.